BrainScope grabs $2.67M from U.S. Army to advance brain injury Dx; FDA extends comment period for unique device ID system;

 @FierceMedDev: Life Technologies and Bristol-Myers Squibb are partnering to develop companion Dx. Who's next? Release | Follow @FierceMedDev

 @MarkHFierce: With all the problems metal hip implants are causing, some good news: at least they don't appear to trigger cancer. Report | Follow @MarkHFierce

 @DamianFierce: Danaher Corp. is spending $338M to pick up Dx company Iris International. News | Follow @DamianFierce

> A New York Times special report looks at the advance medicine has made in using animal tissue scaffolding on which to grow new muscles to repair damaged human limbs. Story (sub. req.)

> BrainScope snagged a $2.67 million contract from the U.S. Army to expand its Ahead device, designed to diagnose brain injuries. More

> Despite its recent plans to slash payroll and close a facility, Covidien ($COV) is projecting its net sales will increase 3% to 6% in fiscal 2013. Release

> The FDA is extending the 60-day comment period for its planned unique device ID system, taking feedback through Oct. 25. Item

> Dune Medical is touting a new study demonstrating that its MarginProbe device is effective in prostate cancer surgeries in addition to those for breast cancer. News

> Auxogyn is launching a new non-invasive early embryo viability diagnostic test in the European Union. Story

> Roche Diagnostics ($RHHBY) got FDA approval for a new cytomegalovirus diagnostic test, launching the assay in the U.S. More

> The 2.3 % medical device tax won't be any boon to medical device companies at all, based on an investment bank analysis of how the Massachusetts health reform law affected companies in the Bay State. Story

Biotech News

 @FierceBiotech: Little NovaDigm races Pfizer, Glaxo in race to develop MRSA  vaccines. Item | Follow @FierceBiotech

 @JohnCFierce: Targacept sharpens well-used budget ax after another drug flames out. More | Follow @JohnCFierce

 @RyanMFierce: Wow. China's BGI buying rival DNA sequencing outfit Complete Genomics for $3.15 per share (value $117.6M). Release | Follow @RyanMFierce

> Sanofi workers plan protests as execs prep for big job cuts next week. Article

> Casualties of an R&D war? Hep C trial patients accuse Bristol-Myers of recklessness. Story

> Threshold shares slammed after lead cancer drug trips on survival goal. News

Pharma News

 @FiercePharma: Sunshine in Australia? Critics call for disclosure of pharma payments to individual docs. Report | Follow @FiercePharma

> Indian drug reps dole out gifts for scripts. Report

> Indian board nixes Bayer's bid to stop generic Nexavar. Article

> French minister backs Sanofi on job-cutting plans. More

> Official French report trashes Pharma, calls many drugs 'useless.' Story

CRO News

> Pfizer launches joint venture with Chinese API maker. Story

> Patheon lifts profit outlook after strong quarter. News

> INC expands clinical ops in South Korea. Article

> Quintiles signs on to sell Sinclair IS drugs in Mexico. More

Biotech IT News

> Boehringer Ingelheim debuts pharma game 'Syrum' on Facebook. Article

> Pfizer taps cloud computing to gain control of supply chain. Story

> Illumina partners with Partners HealthCare to combine sequencing and software. Report

Suggested Articles

Testing company LumiraDx is selling its pandemic virus rapid test across the U.K. targeting individuals without any COVID-19 symptoms.

The FDA has given genomics firm Helix a wider emergency use authorization for its pandemic test.

Celltrion has nabbed a speedy preapproval for its quick pandemic virus test as it forecasts high demand.